earnings
confidence high
sentiment positive
materiality 0.75
ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M
Niagen Bioscience, Inc.
2024-Q2 EPS reported
-$0.01
revenue$44,892,000
- Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).
- Gross margin 60.2%; operating expenses down $0.7M YoY to $13.9M.
- Net loss approximately breakeven, a $2.2M improvement vs Q2 2023 loss of $2.2M.
- Adjusted EBITDA improved to $1.6M from $0.2M in prior year quarter.
- FDA Orphan Drug and Rare Pediatric Disease Designation for nicotinamide riboside chloride in Ataxia Telangiectasia.